MEDP (Lab tools & research services) Stock Valuation & Fair Value Poor on forward returns
MEDP (Lab tools & research services) trades at a current P/E of 36.1, about 21% above its historical normal valuation, with a forward growth estimate of 11.0% and a PEG of 3.27. Analysts' one-year estimates have been hit 22% of the time. Priced at its historical normal P/E of 29.8 on the same blended earnings, the 2026-10-16 close of $618.47 corresponds to about $509 a share. This is a valuation reference, not a price target.
Valuation flags
- Overvalued by 21%
Frequently asked questions
Is MEDP overvalued?
At a current P/E of 36.1 versus its historical normal P/E of 29.8, MEDP trades about 21% above its typical valuation, with a PEG of 3.27 on 11.0% forward growth. tickerseer currently rates it poor on forward returns.
What is MEDP's fair value and PEG?
MEDP trades at a current P/E of 36.1 against a historical normal P/E of 29.8, a PEG of 3.27, and a forward growth estimate of 11.0%. Priced at its historical normal P/E of 29.8 on the same blended earnings, the 2026-10-16 close of $618.47 corresponds to about $509 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of MEDP changed?
tickerseer's rating has been poor on forward returns since 2026-10-17.
Industry: Lab tools & research services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.